P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
20 06 2019
Historique:
received: 01 08 2018
accepted: 13 05 2019
entrez: 22 6 2019
pubmed: 22 6 2019
medline: 10 7 2019
Statut: epublish

Résumé

Sepsis is characterized by a systemic inflammatory response followed by immunosuppression of the host. Metabolic defects and mitochondrial failure are common in immunocompromised patients with sepsis. The NLRP3 inflammasome is important for establishing an inflammatory response after activation by the purinergic P2X7 receptor. Here, we study a cohort of individuals with intra-abdominal origin sepsis and show that patient monocytes have impaired NLRP3 activation by the P2X7 receptor. Furthermore, most sepsis-related deaths are among patients whose NLRP3 activation is profoundly altered. In monocytes from sepsis patients, the P2X7 receptor is associated with mitochondrial dysfunction. Furthermore, activation of the P2X7 receptor results in mitochondrial damage, which in turn inhibits NLRP3 activation by HIF-1α. We show that mortality increases in a mouse model of sepsis when the P2X7 receptor is activated in vivo. These data reveal a molecular mechanism initiated by the P2X7 receptor that contributes to NLRP3 impairment during infection.

Identifiants

pubmed: 31221993
doi: 10.1038/s41467-019-10626-x
pii: 10.1038/s41467-019-10626-x
pmc: PMC6586640
doi:

Substances chimiques

HIF1A protein, human 0
Hif1a protein, mouse 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
Inflammasomes 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
NLRP3 protein, human 0
Nlrp3 protein, mouse 0
P2RX7 protein, human 0
P2rx7 protein, mouse 0
Receptors, Purinergic P2X7 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2711

Subventions

Organisme : Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)
ID : CD13/00059
Pays : International
Organisme : Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)
ID : PI13/00174
Pays : International
Organisme : EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: "Ideas" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013))
ID : 614578
Pays : International
Organisme : Ministerio de Economía, Industria y Competitividad, Gobierno de España (Ministerio de Economía, Industria y Competitividad)
ID : SAF2017-88276-R
Pays : International
Organisme : European Cooperation in Science and Technology (COST)
ID : BM-1406
Pays : International

Références

Blood. 1995 Mar 1;85(5):1341-7
pubmed: 7858264
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
Nat Commun. 2017 Apr 04;8:14919
pubmed: 28374774
Crit Care. 2011;15(1):R27
pubmed: 21244670
Nat Immunol. 2016 Apr;17(4):406-13
pubmed: 26950237
JAMA. 2011 Dec 21;306(23):2594-605
pubmed: 22187279
Nat Immunol. 2016 Sep;17(9):1037-1045
pubmed: 27348412
EMBO J. 2009 Jul 22;28(14):2114-27
pubmed: 19536133
Immunity. 2016 Apr 19;44(4):833-46
pubmed: 27037191
Clin Chim Acta. 2016 Jan 30;453:100-6
pubmed: 26683353
Sci Transl Med. 2016 Nov 23;8(366):366ra162
pubmed: 27881823
J Clin Invest. 2017 Nov 1;127(11):4124-4135
pubmed: 28990935
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
J Clin Invest. 1991 Nov;88(5):1747-54
pubmed: 1939659
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
FASEB J. 2015 Sep;29(9):3626-37
pubmed: 26060214
Crit Care Med. 2007 Dec;35(12):2702-8
pubmed: 18074472
J Clin Immunol. 2000 May;20(3):212-5
pubmed: 10941829
Semin Immunol. 2013 Dec 15;25(6):439-48
pubmed: 24275602
Am J Respir Crit Care Med. 2008 May 1;177(9):983-8
pubmed: 18263805
Crit Care Med. 2009 May;37(5):1649-54
pubmed: 19325482
J Biol Chem. 2005 Oct 7;280(40):33968-76
pubmed: 15994333
J Neurosci. 2015 Mar 4;35(9):3794-805
pubmed: 25740510
Immunity. 2017 Jul 18;47(1):3-5
pubmed: 28723551
Nature. 2008 Jul 24;454(7203):428-35
pubmed: 18650913
Crit Care Med. 2009 Jan;37(1):291-304
pubmed: 19050640
FASEB J. 2016 Dec;30(12):3997-4006
pubmed: 27543123
Nat Commun. 2016 Oct 25;7:13280
pubmed: 27779186
Cell Cycle. 2009 Nov 15;8(22):3723-8
pubmed: 19855167
N Engl J Med. 2013 Aug 29;369(9):840-51
pubmed: 23984731
J Intensive Care Med. 2019 Sep;34(9):740-750
pubmed: 28651474
Sci Rep. 2016 Mar 03;6:22586
pubmed: 26935289
Am J Respir Crit Care Med. 2001 Aug 1;164(3):396-402
pubmed: 11500339
Shock. 2017 Dec;48(6):651-656
pubmed: 28682940
Nat Immunol. 2014 Aug;15(8):727-37
pubmed: 24952505
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1768-73
pubmed: 11734424
J Infect Dis. 1998 May;177(5):1401-5
pubmed: 9593034
Science. 2014 Sep 26;345(6204):1250684
pubmed: 25258083
Oncogene. 2015 Oct 8;34(41):5240-51
pubmed: 25619831
APMIS. 2011 Feb;119(2):155-63
pubmed: 21208283
J Clin Invest. 2016 Oct 3;126(10):3699-3707
pubmed: 27571407
Blood. 1998 Nov 15;92(10):3521-8
pubmed: 9808543
Immunity. 2017 Jul 18;47(1):15-31
pubmed: 28723547
Cell Death Dis. 2012 Aug 16;3:e370
pubmed: 22898868
Front Cell Infect Microbiol. 2017 Apr 06;7:113
pubmed: 28428949
J Immunol. 2017 Feb 1;198(3):1253-1262
pubmed: 28031338
Trends Immunol. 2009 Oct;30(10):475-87
pubmed: 19781994
Nat Immunol. 2014 Aug;15(8):738-48
pubmed: 24952504
Eur J Immunol. 2017 Oct;47(10):1584-1797
pubmed: 29023707
Am J Respir Crit Care Med. 2012 Jun 1;185(11):1225-34
pubmed: 22461369
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15514-9
pubmed: 25313054
Clin Exp Immunol. 2017 Aug;189(2):232-240
pubmed: 28369745
Nat Rev Immunol. 2013 Jun;13(6):397-411
pubmed: 23702978
Crit Care Med. 2005 Dec;33(12 Suppl):S460-2
pubmed: 16340421
J Exp Med. 2011 Dec 19;208(13):2581-90
pubmed: 22110166
J Leukoc Biol. 2017 Jan;101(1):151-164
pubmed: 27272310
Intensive Care Med Exp. 2016 Dec;4(1):22
pubmed: 27430881
Immunity. 2015 Mar 17;42(3):484-98
pubmed: 25746953
J Innate Immun. 2015;7(4):417-27
pubmed: 25675986
Cell. 2016 Oct 6;167(2):457-470.e13
pubmed: 27667687
Nat Med. 1997 Jun;3(6):678-81
pubmed: 9176497
J Infect Dis. 2000 Jan;181(1):176-80
pubmed: 10608764
Crit Care Med. 2011 May;39(5):1056-63
pubmed: 21336129

Auteurs

Juan José Martínez-García (JJ)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Helios Martínez-Banaclocha (H)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Diego Angosto-Bazarra (D)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Carlos de Torre-Minguela (C)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Alberto Baroja-Mazo (A)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Cristina Alarcón-Vila (C)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Laura Martínez-Alarcón (L)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Joaquín Amores-Iniesta (J)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Fátima Martín-Sánchez (F)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Giovanni A Ercole (GA)

Unidad de Reanimación, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Carlos M Martínez (CM)

Plataforma de Patología, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Murcia, 30120, Spain.

Ada González-Lisorge (A)

Unidad de Reanimación, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

José Fernández-Pacheco (J)

Unidad de Reanimación, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Piedad Martínez-Gil (P)

Unidad de Reanimación, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Sahil Adriouch (S)

Normandie University, UNIROUEN, INSERM, U1234, Rouen, 76183, France.

Friedrich Koch-Nolte (F)

Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, D-20246, Germany.

Juan Luján (J)

Servicio de Cirugía General, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Francisco Acosta-Villegas (F)

Unidad de Reanimación, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Pascual Parrilla (P)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.
Servicio de Cirugía General, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Carlos García-Palenciano (C)

Unidad de Reanimación, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain.

Pablo Pelegrin (P)

Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 30120, Spain. pablo.pelegrin@imib.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH